Puma Biotechnology Inc (PBYI): Price and Financial Metrics

Puma Biotechnology Inc (PBYI): $5.30

0.28 (-5.02%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add PBYI to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#40 of 363

in industry

PBYI Price/Volume Stats

Current price $5.30 52-week high $7.73
Prev. close $5.58 52-week low $2.13
Day low $5.24 Volume 275,380
Day high $5.60 Avg. volume 626,848
50-day MA $5.53 Dividend yield N/A
200-day MA $3.99 Market Cap 255.50M

PBYI Stock Price Chart Interactive Chart >

PBYI POWR Grades

  • PBYI scores best on the Value dimension, with a Value rank ahead of 99.55% of US stocks.
  • PBYI's strongest trending metric is Quality; it's been moving up over the last 26 weeks.
  • PBYI's current lowest rank is in the Momentum metric (where it is better than 10.87% of US stocks).

PBYI Stock Summary

  • PUMA BIOTECHNOLOGY INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 92.63% of US listed stocks.
  • PBYI's current price/earnings ratio is 56.18, which is higher than 87.68% of US stocks with positive earnings.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 7.05 for PUMA BIOTECHNOLOGY INC; that's greater than it is for 83.84% of US stocks.
  • If you're looking for stocks that are quantitatively similar to PUMA BIOTECHNOLOGY INC, a group of peers worth examining would be ATEN, CSGS, VMEO, ALKS, and ALSN.
  • PBYI's SEC filings can be seen here. And to visit PUMA BIOTECHNOLOGY INC's official web site, go to www.pumabiotechnology.com.

PBYI Valuation Summary

  • In comparison to the median Healthcare stock, PBYI's price/sales ratio is 78.57% lower, now standing at 0.9.
  • Over the past 142 months, PBYI's EV/EBIT ratio has gone up 35.4.

Below are key valuation metrics over time for PBYI.

Stock Date P/S P/B P/E EV/EBIT
PBYI 2023-12-29 0.9 5.3 55.4 13.3
PBYI 2023-12-28 0.9 5.3 55.7 13.3
PBYI 2023-12-27 0.9 5.3 55.6 13.3
PBYI 2023-12-26 0.9 5.5 57.1 13.6
PBYI 2023-12-22 0.9 5.1 52.7 12.7
PBYI 2023-12-21 0.8 4.8 50.4 12.2

PBYI Growth Metrics

    The 4 year cash and equivalents growth rate now stands at -15.69%.
  • Its 3 year cash and equivalents growth rate is now at 20.35%.
  • Its 2 year cash and equivalents growth rate is now at -30.71%.
PBYI's revenue has moved down $54,547,000 over the prior 33 months.

The table below shows PBYI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 217.713 -28.945 9.832
2022-06-30 206.856 -35.706 -34.48
2022-03-31 200.722 -21.906 -48.957
2021-12-31 253.155 20.65 -29.126
2021-09-30 250.355 20.45 -48.244
2021-06-30 254.864 11.672 -35.035

PBYI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PBYI has a Quality Grade of C, ranking ahead of 66.91% of graded US stocks.
  • PBYI's asset turnover comes in at 1.012 -- ranking 23rd of 682 Pharmaceutical Products stocks.
  • ACAD, TVTX, and CTMX are the stocks whose asset turnover ratios are most correlated with PBYI.

The table below shows PBYI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 1.012 0.749 -0.448
2021-06-30 0.995 0.755 -0.266
2021-03-31 1.058 0.780 -0.137
2020-12-31 0.905 0.825 -0.449
2020-09-30 0.955 0.836 -0.355
2020-06-30 1.008 0.842 -0.212

PBYI Price Target

For more insight on analysts targets of PBYI, see our PBYI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $8.63 Average Broker Recommendation 2.06 (Hold)

Puma Biotechnology Inc (PBYI) Company Bio


Puma Biotechnology is a development stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of products for the treatment of various forms of cancer. The company was founded in 2010 and is based in Los Angeles, California.


PBYI Latest News Stream


Event/Time News Detail
Loading, please wait...

PBYI Latest Social Stream


Loading social stream, please wait...

View Full PBYI Social Stream

Latest PBYI News From Around the Web

Below are the latest news stories about PUMA BIOTECHNOLOGY INC that investors may wish to consider to help them evaluate PBYI as an investment opportunity.

Iovance (IOVA) Falls After Clinical Update on Lung Cancer Drug

Iovance (IOVA) is likely to pause enrollment in the phase II IOV-LUN-202 study evaluating its tumor infiltrating lymphocyte therapy, LN-145, for treating non-small cell lung cancer. Stock declines.

Yahoo | December 28, 2023

Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca Onbody

The FDA approves Coherus' (CHRS) Udenyca Onbody, an on-body injector presentation of Udenyca (pegfilgrastim-cbqv). Shares of the company rise on the news.

Yahoo | December 28, 2023

Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate

The FDA clears Senti Bio's (SNTI) investigational new drug application for SENTI-202 for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia. Stock rises.

Yahoo | December 26, 2023

Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis

Cidara's (CDTX) Rezzayo (rezafungin acetate) gets approval from the European Commission for the treatment of invasive candidiasis in adults. The stock rises 11.1%.

Yahoo | December 26, 2023

Sanofi (SNY) Discontinues Tusamitamab Ravtansine Cancer Program

Sanofi (SNY) stops the development of tusamitamab ravtansine after a phase III study on the candidate for second-line metastatic non-small cell lung cancer fails to meet the primary endpoint.

Yahoo | December 22, 2023

Read More 'PBYI' Stories Here

PBYI Price Returns

1-mo -17.96%
3-mo 22.40%
6-mo 101.52%
1-year 107.84%
3-year -44.44%
5-year -86.34%
YTD 22.40%
2023 2.36%
2022 39.14%
2021 -70.37%
2020 17.26%
2019 -57.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!